Phathom Pharmaceuticals, Inc. cash flow to debt ratio of -78.74% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Phathom Pharmaceuticals, Inc.'s free cash flow has increased -37.52% from $-266.90M last year to $-166.78M, signaling increasing performance

Phathom Pharmaceuticals, Inc.'s debt to equity ratio is -0.49, signaling that the company spent its equity and risk bankruptcy.

Phathom Pharmaceuticals, Inc.'s debt to equity ratio is -0.49, signaling that the company spent its equity and risk bankruptcy.

Phathom Pharmaceuticals, Inc. has negative EBITDA, making leverage ratio unreliable

Phathom Pharmaceuticals, Inc.'s interest coverage ratio is -0.64, which means that the company struggles to meet interest obligations, signaling financial risk.

Phathom Pharmaceuticals, Inc.'s profit margin has increased (-93.17%) in the last year from -605.09% to -41.34%, signaling increasing performance

Phathom Pharmaceuticals, Inc.'s short-term assets of $228.97M exceed its short-term liabilities of $132.04M

Phathom Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Phathom Pharmaceuticals, Inc.'s return on equity of 25.70%, is higher than 15.00%, indicating good performance

Phathom Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Phathom Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Phathom Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Phathom Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Phathom Pharmaceuticals, Inc.'s yearly earnings has increased -33.82% since last year from $-334.33M to $-221.25M, signaling increasing performance

Phathom Pharmaceuticals, Inc.'s yearly revenue has increased 216.93% since last year from $55.25M to $175.11M, signaling increasing performance

ROIC -23.36% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Phathom Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Phathom Pharmaceuticals, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Phathom Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Phathom Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Phathom Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Phathom Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Phathom Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Phathom Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Phathom Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Phathom Pharmaceuticals, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Phathom Pharmaceuticals, Inc. has a price-to-sales ratio of 2.99x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue